

Discloser Identifier: 1098363

Disclosure Purpose: 22-13082

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer Pharmaceuticals LLC	Employment	Self
<i>Title:</i> Associate Director <i>Additional Information:</i>	<i>Position Description:</i> Study Statistician on COVID-19 studies	

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

A Bivalent Omicron-BA.1-Adapted BNT162b2 COVID-19 Booster in >55-Year-Olds

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Sandra Buitrago

Discloser Identifier: 1098367

Disclosure Purpose: 22-13082

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

A Bivalent Omicron-BA.1-Adapted BNT162b2 COVID-19 Booster in >55-Year-Olds (22-13082)

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Jose Cardona

Discloser Identifier: 978408

Disclosure Purpose: 22-13082

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

A Bivalent Omicron-BA.1-Adapted BNT162b2 COVID-19 Booster in >55-Year-Olds

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

David Cooper

Discloser Identifier: 970668

Disclosure Purpose: 22-13082

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Executive Director <i>Additional Information:</i>		<i>Position Description:</i> Vaccine Researcher
Pfizer	Stock	Self
<i>Additional Information:</i>		
Pfizer	Stock Option	Self
Additional Information:		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

A Bivalent Omicron-BA.1-Adapted BNT162b2 COVID-19 Booster in >55-Year-Olds

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Douglas Denham

Discloser Identifier: 1063624

Disclosure Purpose: 22-13082

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

A Bivalent Omicron-BA.1-Adapted BNT162b2 COVID-19 Booster in >55-Year-Olds

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1098361

Disclosure Purpose: 22-13082

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

A Bivalent Omicron-BA.1-Adapted BNT162b2 COVID-19 Booster in >55-Year-Olds

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1063625

Disclosure Purpose: 22-13082

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AstraZeneca	Grant / Contract	Self
<i>Recipient Name:</i> David Fitz-Patrick, M.D., Inc <i>Grant / Contract Description:</i> Grant support for clinical trials <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Moderna	Grant / Contract	Self
<i>Recipient Name:</i> David Fitz-Patrick, M.D., Inc <i>Grant / Contract Description:</i> Grant support for clinical trials <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Pfizer Inc.	Grant / Contract	Self
<i>Recipient Name:</i> David Fitz-Patrick, M.D., Inc <i>Grant / Contract Description:</i> Grant support for clinical trials <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Safety and Immunogenicity of Omicron-Modified BA.1 adapted BNT162b2 COVID-19 Vaccine in participants >55yrs of age

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Juleen Gayed

Discloser Identifier: 1063596

Disclosure Purpose: 22-13082

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer Limited	Employment	Self
<i>Title:</i> Director Clinical Research MD <i>Additional Information:</i>		<i>Position Description:</i>
Pfizer Limited	Stock	Self
<i>Additional Information:</i>		
Pfizer Limited	Stock Option	Self
<i>Additional Information:</i>		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

A Bivalent Omicron-BA.1-Adapted BNT162b2 COVID-19 Booster in >55-Year-Olds

3. Are you the corresponding author?

Yes.

a. Please list the other authors' names here.

Patricia Winokur, MD, David Fitz-Patrick, MD, Stephen J. Thomas, MD, Oyenyi Diya, MD, Stephen Lockhart, DM, Xia Xu, PhD, Ying Zhang, PhD, Vishva Bangad, MS, Howard I. Schwartz, MD, Douglas Denham, DO, Jose F. Cardona, MD, JD, MBA-HA, Lisa Usdan, MD, John Ginis, BS, Federico Mensa, MD, Jing Zou, PhD, Xuping Xie, PhD, Pei-Yong Shi, PhD, Claire Lu, PhD, Sandra Buitrago, MS, Ingrid L. Scully, PhD, David Cooper, PhD, Kenneth Koury, PhD, Kathrin U. Jansen, PhD, Özlem Türeci, MD, Uğur Şahin, MD, Kena A. Swanson, PhD, William C. Gruber, MD, Nicholas Kitchin, MD

Certification

I certify that the information provided in this disclosure is complete and accurate.

John Ginis

Discloser Identifier: 737730

Disclosure Purpose: 22-13082

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Senior Director, Clinical Scientist <i>Additional Information:</i>		<i>Position Description:</i>

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

A Bivalent Omicron-BA.1-Adapted BNT162b2 COVID-19 Booster in >55-Year-Olds

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 627453

Disclosure Purpose: 22-13082

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Senior Vice President <i>Additional Information:</i>		<i>Position Description:</i> Vaccine Clinical Research and Development Worldwide Research Development and Medical
Pfizer	Stock	Self
<i>Additional Information:</i>		
Pfizer	Stock Option	Self
<i>Additional Information:</i>		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

A Bivalent Omicron-BA.1-Adapted BNT162b2 COVID-19 Booster in >55-Year-Olds

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

kathrin Jansen

Discloser Identifier: 627443

Disclosure Purpose: 22-13082

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> vaccine consultant <i>Additional Information:</i> less than 10 hours a week		
Pfizer Inc.	Stock	Self
<i>Additional Information:</i> shareholder		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

A Bivalent Omicron-BA.1-Adapted BNT162b2 COVID-19 Booster in >55-Year-Olds

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 970660

Disclosure Purpose: 22-13082

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Vice President <i>Additional Information:</i> Full time employee		<i>Position Description:</i> Vaccine Clinical Research and Development
Pfizer	Stock	Self
<i>Additional Information:</i>		
Pfizer	Stock Option	Self
Additional Information:		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

A Bivalent Omicron-BA.1-Adapted BNT162b2 COVID-19 Booster in >55-Year-Olds

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Kenneth Koury

Discloser Identifier: 970666

Disclosure Purpose: 22-13082

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Executive Director <i>Additional Information:</i>		<i>Position Description:</i> Head of Statistics and Modeling, Vaccine Clinical Research and Development
Pfizer	Stock	Self
<i>Additional Information:</i>		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

A Bivalent Omicron-BA.1-Adapted BNT162b2 COVID-19 Booster in >55-Year-Olds

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 970661

Disclosure Purpose: 22-13082

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Vice President <i>Additional Information:</i>		<i>Position Description:</i> Clinical Research Head Vaccines Europe and Asia Pacific
Pfizer	Stock	Self
<i>Additional Information:</i>		
Pfizer	Stock Option	Self
Additional Information:		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

A Bivalent Omicron-BA.1-Adapted BNT162b2 COVID-19 Booster in >55-Year-Olds

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Claire Lu

Discloser Identifier: 1063600

Disclosure Purpose: 22-13082

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Director <i>Additional Information:</i>		<i>Position Description:</i>
Pfizer	Stock	Self
<i>Additional Information:</i>		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

A Bivalent Omicron-BA.1-Adapted BNT162b2 COVID-19 Booster in >55-Year-Olds

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1098366

Disclosure Purpose: 22-13082

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
BioNTech	Employment	Self
<i>Title:</i> Vice President Clinical Development Infectious Diseases <i>Additional Information:</i>		<i>Position Description:</i> Responsible for the clinical development of vaccines and therapeutics for Infectious Diseases.
BioNTech	Stock	Self
<i>Additional Information:</i> I have restricted stock units (RSUs) and I may have stocks at the time of the publication of the article		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

A Bivalent Omicron-BA.1-Adapted BNT162b2 COVID-19 Booster in >55-Year-Olds

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 970674

Disclosure Purpose: 22-13082

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
biontech	Fiduciary Officer	Self
<i>Official Title:</i> Chief Executive Officer, Co-Founder <i>Additional Information:</i>		<i>Position Description:</i> Member of the Board
biontech	Stock	Self
<i>Additional Information:</i>		
biontech	Stock Option	Self
Additional Information:		

Intellectual Property

Type	Is Licensed	Interest Held By
Patent - 3 UTR Sequences for stabilisation of mRNA	-	Self
<i>Description:</i> 3 UTR Sequences for stabilisation of mRNA <i>Patent Status:</i> Pending <i>Filing Jurisdiction:</i> USA <i>Licensees:</i>		<i>Patent Number:</i> EPPCT/EP2015/073180, US 20190071682 <i>Patent Holder:</i> Previous Institution
Licensee	Title	Date
biontech		
<i>Additional Information:</i> I am co-inventors on various patents on RNA Technologies, both pending and granted, which have been filed over a period of 10+ years, some of which are licensed to third parties. Jurisdictions are Broad including US, EU, Asia.		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

A Bivalent Omicron-BA.1-Adapted BNT162b2 COVID-19 Booster in >55-Year-Olds

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Howard schwartz

Discloser Identifier: 1098364

Disclosure Purpose: 22-13082

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

A Bivalent Omicron-BA.1-Adapted BNT162b2 COVID-19 Booster in >55-Year-Olds

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1098368

Disclosure Purpose: 22-13082

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer Inc.	Employment	Self
<i>Title:</i> Executive Director Vaccine Research & Development <i>Additional Information:</i>		<i>Position Description:</i> vaccine immunologist supporting vaccine R&D
Pfizer Inc.	Stock	Self
<i>Additional Information:</i> employee stock incentives		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

A Bivalent Omicron-BA.1-Adapted BNT162b2 COVID-19 Booster in >55-Year-Olds

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Pei-Yong Shi

Discloser Identifier: 717400

Disclosure Purpose: 22-13082

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer Inc.	Grant / Contract	Self
<i>Recipient Name:</i> Pei-Yong Shi <i>Grant / Contract Description:</i> Contract <i>Additional Information:</i> Sample testing		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

A Bivalent Omicron-BA.1-Adapted BNT162b2 COVID-19 Booster in >55-Year-Olds

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Kena Swanson

Discloser Identifier: 970664

Disclosure Purpose: 22-13082

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Vice President, Viral Vaccines <i>Additional Information:</i>		<i>Position Description:</i> vaccine research and development
Pfizer	Stock	Self
<i>Additional Information:</i>		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

A Bivalent Omicron-BA.1-Adapted BNT162b2 COVID-19 Booster in >55-Year-Olds

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 776591

Disclosure Purpose: 22-13082

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Clover Biopharmaceuticals	End Point Review Committee	Self
<p><i>Category:</i> End Point Review Committee <i>Description:</i> case adjudication committee <i>Additional Information:</i> adjudicate covid cases reported during conduct of covid vaccine trial</p>		
EdJen Biotech	Consultant	Self
<p><i>Category:</i> Consultant <i>Description:</i> scientific ad board <i>Additional Information:</i> single meeting</p>		
Icosavax	Data And Safety Monitoring	Self
<p><i>Category:</i> Data And Safety Monitoring <i>Description:</i> covid vaccine DSMB <i>Additional Information:</i> DSMB for covid vaccine trial</p>		
New Day Diagnostics	Consultant	Self
<p><i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i> one time speaker engagement on covid</p>		
Pfizer	Consultant	Self
<p><i>Category:</i> Consultant <i>Description:</i> mRNA vaccine ad board, vaccine roll out KOL, scientific communications KOL, conference speaker <i>Additional Information:</i> various compensation for time, travel expenses</p>		
Rheonix	Consultant	Self
<p><i>Category:</i> Consultant <i>Description:</i> Scientific advisory board member and chief medical officer <i>Additional Information:</i> COVID diagnostics developer, SAB member and Chief Medical Officer</p>		
Vaxxinity	Consultant	Self
<p><i>Category:</i> Consultant <i>Description:</i> DSMB member <i>Additional Information:</i> DSMB member reviewing safety data from trials, 2 meetings</p>		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes.

a. Please describe those relationships.

I have disclosed any and all relationships related to COVID. I have not disclosed all relationships related to vaccines in general or mRNA technology platforms.

2. What is the manuscript title?

A Bivalent Omicron-BA.1-Adapted BNT162b2 COVID-19 Booster in >55-Year-Olds

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 970670

Disclosure Purpose: 22-13082

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
biontech	Employment	Self
<i>Title:</i> Chief Medical Officer <i>Additional Information:</i> also spouse is board member and CEO of Company since 2008		<i>Position Description:</i> Board member, CO-founder
biontech	Fiduciary Officer	Self
<i>Official Title:</i> Chief Medical Officer <i>Additional Information:</i> also spouse is co-founder and board member (Chief Executive Officer) of Biontech		<i>Position Description:</i> board member, co-founder
biontech	Stock Option	Self
Additional Information: self and spouse have stock Options. spouse has stock		

Intellectual Property

Type	Is Licensed	Interest Held By
Patent - Modifications of RNA leading to increased transcr	-	Self
<i>Description:</i> Modifications of RNA leading to increased transcript stability and translational efficiency <i>Patent Status:</i> Pending <i>Filing Jurisdiction:</i> USA <i>Licensees:</i>		<i>Patent Number:</i> EP1934345B9, DE102005046490.4 <i>Patent Holder:</i> Current Institution
Licensee	Title	Date
biontech		
<i>Additional Information:</i> self and spouse are co-inventors on various patents on RNA Tech		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

A Bivalent Omicron-BA.1-Adapted BNT162b2 COVID-19 Booster in >55-Year-Olds

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Discloser Identifier: 1098365

Disclosure Purpose: 22-13082

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

A Bivalent Omicron-BA.1-Adapted BNT162b2 COVID-19 Booster in >55-Year-Olds

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Patricia Winokur

Discloser Identifier: 335414

Disclosure Purpose: 22-13082

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
PFIZER CANADA INC	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Served on Pfizer advisory board <i>Additional Information:</i> Approximately 5 hours of commitment		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Safety and Immunogenicity of Omicron BA.1 adapted BNT162b2 COVID 19 Vaccine in participants greater than 55 years of age.

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 996937

Disclosure Purpose: 22-13082

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer Inc.	Grant / Contract	Self
<i>Recipient Name:</i> Xuping Xie <i>Grant / Contract Description:</i> Pfizer's contract supports the testing of the specimens <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

A Bivalent Omicron-BA.1-Adapted BNT162b2 COVID-19 Booster in >55-Year-Olds

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1017534

Disclosure Purpose: 22-13082

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Sr. Director, Vaccine Statistics <i>Additional Information:</i>		<i>Position Description:</i> Design, conduct, and analysis of vaccine clinical trials

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

A Bivalent Omicron-BA.1-Adapted BNT162b2 COVID-19 Booster in >55-Year-Olds

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1098362

Disclosure Purpose: 22-13082

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer Inc.	Employment	Self
<i>Title:</i> Director <i>Additional Information:</i>		<i>Position Description:</i> Biostatistics

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

A Bivalent Omicron-BA.1-Adapted BNT162b2 COVID-19 Booster in >55-Year-Olds

3. **Are you the corresponding author?**

No

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 996939

Disclosure Purpose: 22-13082

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer Inc.	Grant / Contract	Self
<i>Recipient Name:</i> Jing Zou <i>Grant / Contract Description:</i> Pfizer's contract supports the testing of the specimens <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

A Bivalent Omicron-BA.1-Adapted BNT162b2 COVID-19 Booster in >55-Year-Olds

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.